From WikiMD

Information about Ibalizumab

Ibalizumab is a humanized monoclonal antibody to CD4, the cell surface receptor for the HIV-1 envelope glycoprotein (gp120), which is used to treat patients with multidrug resistant HIV-1 infection.

Liver safety of Ibalizumab

Ibalizumab therapy has not been associated with serum enzyme elevations or to instances of clinically apparent drug induced liver injury.

Mechanism of action of Ibalizumab

Ibalizumab (eye' ba liz' ue mab) is a recombinant humanized monoclonal antibody to CD4, the cell surface receptor for the HIV-1 envelope glycoprotein 120 (gp120). Ibalizumab does not block the binding of gp120 to CD4 but rather inhibits the conformation changes in the CD4/gp120 complex that allows binding to a second cellular receptor, chemokine-receptor-4 (CXCR4), thus inhibiting HIV replication. Clinical trials of ibalizumab in heavily treatment-experienced HIV-positive patients with multidrug resistance have shown that it decreased HIV RNA levels and resulted in full suppression in over half of patients.

FDA approval information for Ibalizumab

Ibalizumab was approved for use in the United States in 2018 for therapy (in combination with other antiretroviral agents) of patients with multidrug resistant HIV-1 infection.

Dosage and administration for Ibalizumab

Ibalizumab is available in solution in single dose vials of 200 mg/1.33 mL under the brand name Trogarzo. Ibalizumab is administered as an intravenous infusion. The recommended dose is an initial loading dose of 2,000 mg followed by a maintenance dose of 800 mg every 2 weeks.

Side effects of Ibalizumab

Side effects are generally mild and include injection site reactions, diarrhea, dizziness, nausea and rash. Rare but potentially severe adverse events include hypersensitivity reactions and immune reconstitution syndrome.

Antiviral agents

Drugs for HIV Infection, in the Subclass Antiretroviral Agents

Drugs for Hepatitis B

Drugs for Hepatitis C

HCV NS5A Inhibitors

HCV NS5B (Polymerase) Inhibitors

HCV Protease Inhibitors

Combination Therapies

Drugs for Herpes Virus Infections (HSV, CMV, others)

Drugs for Influenza

The article on Ibalizumab is a stub. YOU can help Wikimd by expanding it!

Medication resources

Learn more


About WikiMD

About us: WikiMD is a free medical encyclopedia and wellnesspedia moderated by medical professionals.

Our mission: Provide up to date physician reviewed health, nutrition and wellness information for free in over 100 languages.

Join us: This article is a stub. Help improve Ibalizumab or others. Do not trust amateurs with your life! Join us in this effort!. Paid editors welcome.

Pubmed.png Uptodate.png Wikipedia Reddit YouTube videos
W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Ibalizumab">Ibalizumab</a>

  • Individual results may vary for weight loss from our sponsors.